SG Americas Securities LLC Buys 7,849 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

SG Americas Securities LLC raised its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 71.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,840 shares of the pharmaceutical company’s stock after acquiring an additional 7,849 shares during the period. SG Americas Securities LLC’s holdings in GSK were worth $730,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. MADDEN SECURITIES Corp boosted its holdings in GSK by 22.2% in the first quarter. MADDEN SECURITIES Corp now owns 106,830 shares of the pharmaceutical company’s stock valued at $4,139,000 after acquiring an additional 19,400 shares during the last quarter. GAMMA Investing LLC boosted its holdings in GSK by 107.8% in the first quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company’s stock valued at $172,000 after acquiring an additional 2,307 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in GSK by 50.1% in the first quarter. Farther Finance Advisors LLC now owns 6,085 shares of the pharmaceutical company’s stock valued at $230,000 after acquiring an additional 2,030 shares during the last quarter. Range Financial Group LLC boosted its holdings in GSK by 7.7% during the first quarter. Range Financial Group LLC now owns 9,135 shares of the pharmaceutical company’s stock worth $354,000 after buying an additional 652 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in GSK by 47.8% during the first quarter. Park Avenue Securities LLC now owns 77,630 shares of the pharmaceutical company’s stock worth $3,007,000 after buying an additional 25,111 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Trading Down 1.7%

Shares of GSK stock opened at $37.99 on Friday. The stock has a market capitalization of $77.79 billion, a PE ratio of 19.58, a P/E/G ratio of 1.35 and a beta of 0.52. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The business has a 50-day moving average of $38.58 and a 200 day moving average of $36.81. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. During the same quarter in the previous year, the business earned $0.43 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a $0.4216 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.44%. GSK’s dividend payout ratio is 87.11%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GSK shares. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price target on the stock. Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. Berenberg Bank reaffirmed a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, GSK presently has an average rating of “Hold” and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.